Astrazeneca (AZN) Other Working Capital Changes (2009 - 2021)

Astrazeneca has reported Other Working Capital Changes for 12 years, with the latest figure at $1.2 billion in Q3 2021.

• On a quarterly basis, Other Working Capital Changes rose 129.71% year-over-year to $1.2 billion in Q3 2021; TTM through Sep 2021 was $1.8 billion, a 400.83% increase from a year earlier, with the FY2020 full-year figure at $361.0 million, up 204.34% from the prior year.
• Other Working Capital Changes was $1.2 billion for Q3 2021 at Astrazeneca, up from -$353.0 million in the prior quarter.
• The five-year high for Other Working Capital Changes was $1.2 billion in Q1 2021, with the low at -$993.0 million in Q1 2018.
• Average Other Working Capital Changes over 5 years is -$81.9 million, with a median of -$335.0 million recorded in 2020.
• The sharpest annual moves came in 2017 and 2021: Other Working Capital Changes plunged 1485.94% in 2017, then soared 371.91% in 2021.
• Over 5 years, Other Working Capital Changes stood at -$228.0 million in 2017, then plunged by 335.53% to -$993.0 million in 2018, then jumped by 65.16% to -$346.0 million in 2019, then increased by 26.3% to -$255.0 million in 2020, then surged by 572.94% to $1.2 billion in 2021.
• The last three Other Working Capital Changes figures came in at $1.2 billion (Q3 2021), -$353.0 million (Q2 2021), and $1.2 billion (Q1 2021), per Business Quant data.